ravagalimab

Ravagalimab is a monoclonal antibody developed by AbbVie that functions as a CD40 antagonist. It binds to the CD40 receptor, a member of the tumor necrosis factor (TNF) receptor family, and inhibits its activation. CD40 plays an important role in lymphocyte activation and antigen-presenting cell function, making it a key target in immune-mediated diseases. Ravagalimab has been investigated primarily for the treatment of moderate to severe ulcerative colitis and Sjogren's syndrome, with previous research also targeting Crohn's disease. The drug is administered via intravenous or subcutaneous injection and remains investigational, with no current regulatory approvals[1][2][3][4][5][7].